Chorev M, Rubini E, Hart Y, Gilon C, Wormser U, Selinger Z
Eur J Pharmacol. 1986 Aug 15;127(3):187-95. doi: 10.1016/0014-2999(86)90363-8.
In a search for metabolically stable analogues of substance P (SP) the hexapeptide [pGlu6]SP-(6-11) was modified by reversal of the direction of a single amide bond. This novel peptide modification reverses the direction of the amide bonds at the peptide backbone but attempt to retain the topology of the amino acid side-chains at the peptide surface. The partial retro-inverso modification was successfully applied in a previous study for enkephalin analogues which were found to have potent and protracted morphinomimetic activity both in vivo and in vitro. The partially modified retro-inverso analogues: [pGlu6 psi(NH-CO)(RS)-Phe7]SP-(6-11) (analogue II) and [pGlu6,Phe8 psi(NH-CO)Gly9]SP-(6-11) (analogue III) were tested on guinea-pig ileum and for K+ release from rat parotid slices. Metabolic stability of the analogues was measured by their ability to produce persistent K+ release from parotid slices, their half life time (t1/2) in the rat parotid and hypothalamic slice systems and their resistance to proteolytic cleavage by chymotrypsin, pepsin, papain and pronase. Analogue II was devoid of biological activity and was slowly degraded in the parotid system and by several proteases. Analogue II was a full agonist of the SP-P receptor with a potency of 22 and 15% of the parent compound I, in the guinea-pig ileum and parotid slice system respectively. Pretreatment of the guinea-pig ileum with atropine (0.3 microM) had no effect on the potency of analogue III. On the other hand, when tested on rat vas deferens (an SP-E system), analogue III was about 20-fold more potent than the parent compound I.(ABSTRACT TRUNCATED AT 250 WORDS)
为寻找P物质(SP)代谢稳定的类似物,六肽[pGlu6]SP-(6 - 11)通过反转单个酰胺键的方向进行了修饰。这种新型肽修饰反转了肽主链上酰胺键的方向,但试图保留肽表面氨基酸侧链的拓扑结构。部分反转修饰已成功应用于先前对脑啡肽类似物的研究,这些类似物在体内和体外均具有强效且持久的吗啡样活性。对部分修饰的反转类似物:[pGlu6 psi(NH - CO)(RS)-Phe7]SP-(6 - 11)(类似物II)和[pGlu6,Phe8 psi(NH - CO)Gly9]SP-(6 - 11)(类似物III)进行了豚鼠回肠试验以及大鼠腮腺切片钾离子释放试验。通过类似物从腮腺切片产生持续钾离子释放的能力、它们在大鼠腮腺和下丘脑切片系统中的半衰期(t1/2)以及它们对胰凝乳蛋白酶、胃蛋白酶、木瓜蛋白酶和链霉蛋白酶蛋白水解切割的抗性来测量类似物的代谢稳定性。类似物II没有生物活性,在腮腺系统中以及被几种蛋白酶缓慢降解。在豚鼠回肠和腮腺切片系统中,类似物II分别是SP - P受体的完全激动剂,效力为母体化合物I的22%和15%。用阿托品(0.3 microM)预处理豚鼠回肠对类似物III的效力没有影响。另一方面,在大鼠输精管(一个SP - E系统)上进行测试时,类似物III的效力比母体化合物I高约20倍。(摘要截短于250字)